肝脏影像报告和数据系统瘤栓分类:系统评价与Meta分析
该系统评价与Meta分析纳入16项研究共150例LI-RADS瘤栓分类(LR-TIV),汇总显示LR-TIV病因中肝细胞癌占70.9%(95%CI 55.7-82.5%;I²=59%),非肝细胞癌占29.2%(95%CI 17.5-44.4%;I²=59%)。仅以病理为参考标准的研究中肝细胞癌比例较低(67.1%;95%CI 49.3-81.1%),而以丙型肝炎为主要基础肝病的研究中比例较高(81.9%;95%CI 11.3-99.4%);研究类型与异质性显著相关(p=0.04)。
要点
- LR-TIV最常见的病因是肝细胞癌,汇总占比70.9%(95%CI 55.7-82.5%)。
- 非肝细胞癌占LR-TIV的29.2%(95%CI 17.5-44.4%),报告时需结合参考标准与地域差异。
- 仅以病理为参考标准时肝细胞癌比例较低(67.1%;95%CI 49.3-81.1%)。
核心结论
- LR-TIV最常见的病因是肝细胞癌,汇总比例为70.9%(95%CI 55.7-82.5%;I²=59%)。
- 理解LR-TIV中肝细胞癌与非肝细胞癌的占比时,可能需考虑参考标准类型、地域差异和研究设计。
研究设计与样本
- 系统评价与Meta分析,检索MEDLINE和EMBASE截至2020年7月7日,纳入16项报告LR-TIV病因的原始研究,共150例LR-TIV。
- 按参考标准类型和最常见基础肝病进行亚组分析,采用Meta回归探索研究异质性。
诊断标准与关键数值
- 150例LR-TIV中,98例(65%)为肝细胞癌,52例(35%)为非肝细胞癌。
- 汇总肝细胞癌比例为70.9%(95%CI 55.7-82.5%;I²=59%),非肝细胞癌比例为29.2%(95%CI 17.5-44.4%;I²=59%)。
- 仅以病理为参考标准的研究中,肝细胞癌汇总比例为67.1%(95%CI 49.3-81.1%)。
- 以丙型肝炎为最常见基础肝病的研究中,肝细胞癌汇总比例为81.9%(95%CI 11.3-99.4%)。
- 研究类型(队列研究 vs 病例对照研究)与研究异质性显著相关(p=0.04)。
临床应用与阅片要点
- 阅片报告LR-TIV时,应意识到肝细胞癌是最常见病因,但非肝细胞癌约占29.2%。
- 参考标准类型和地域差异可能影响LR-TIV中肝细胞癌的占比,解读文献数值时需结合研究条件。
- 研究设计(队列 vs 病例对照)是异质性来源之一,比较不同研究结果时需考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to systematically determine the etiology of the Liver Imaging Reporting and Data System (LI-RADS) tumor-in-vein category (LR-TIV) on contrast-enhanced CT or MRI and to determine the sources of heterogeneity between reported results.
METHODS: Original studies reporting the etiology of LR-TIV were identified in MEDLINE and EMBASE up until July 7, 2020. The meta-analytic pooled percentages of HCC and non-HCC in LR-TIV were calculated. Subgroup analyses were performed according to the type of reference standard and the most common underlying liver disease. Meta-regression analysis was performed to explore study heterogeneity.
RESULTS: Sixteen studies reported the etiology of a total of 150 LR-TIV, of which 98 (65%) were HCC and 52 (35%) were non-HCC. The meta-analytic pooled percentages of HCC and non-HCC in LR-TIV were 70.9% (95% confidence interval [CI], 55.7-82.5%; I2 = 59%) and 29.2% (95% CI, 17.5-44.4%; I2 = 59%), respectively. The meta-analytic pooled percentage of HCC was lower in studies using only pathology as a reference standard (67.1%; 95% CI, 49.3-81.1%), but higher in studies in which hepatitis C was the most common underlying liver disease (81.9%; 95% CI, 11.3-99.4%) than that in the total 16 studies. Study type (cohort study versus case-control study) was significantly associated with study heterogeneity (p = 0.04).
CONCLUSION: The most common etiology of LR-TIV was HCC. It might be important to understand the percentage of HCC and non-HCC in LR-TIV in consideration of the type of reference standard, geographic differences, and study design.
KEY POINTS: • The most common etiology of Liver Imaging Reporting and Data System (LI-RADS) tumor-in-vein category (LR-TIV) was hepatocellular carcinoma (HCC). • The percentage of HCC in LR-TIV was relatively low in studies using only pathology as a reference standard, but high in studies in which hepatitis C was the most common underlying liver disease. • Study type was a factor significantly influencing study heterogeneity.
引用
- Kim DH, Choi SH, Park SH, et al. The Liver Imaging Reporting and Data System tumor-in-vein category: a systematic review and meta-analysis. Eur Radiol. 2020. PMID: 33001305. doi:10.1007/s00330-020-07282-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。